Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
NCT ID: NCT00460408
Last Updated: 2012-12-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
501 participants
OBSERVATIONAL
2006-08-31
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational study, no comparator
Observational study of patients with AMD treated with Macugen, no comparator
Macugen
Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Macugen
Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Brussels, , Belgium
Pfizer Investigational Site
Charleroi, , Belgium
Pfizer Investigational Site
Ieper, , Belgium
Pfizer Investigational Site
Lier, , Belgium
Pfizer Investigational Site
Turnhout, , Belgium
Pfizer Investigational Site
Limassol, , Cyprus
Pfizer Investigational Site
Brno, , Czechia
Pfizer Investigational Site
Hradec Králové, , Czechia
Pfizer Investigational Site
Pilsen, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Sønderborg, , Denmark
Pfizer Investigational Site
Argonay, , France
Pfizer Investigational Site
Dijon, , France
Pfizer Investigational Site
Grenoble, , France
Pfizer Investigational Site
Le Golfe Juan, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Rennes, , France
Pfizer Investigational Site
Augsburg, , Germany
Pfizer Investigational Site
Frankfurt, , Germany
Pfizer Investigational Site
Karlsruhe, , Germany
Pfizer Investigational Site
Konstanz, , Germany
Pfizer Investigational Site
Ludwigshafen, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Münster, , Germany
Pfizer Investigational Site
Weilheim, , Germany
Pfizer Investigational Site
Heraklion, Crete, Greece
Pfizer Investigational Site
Nikaia, Piraeus, Greece
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
Heraklion, , Greece
Pfizer Investigational Site
Ioannina, , Greece
Pfizer Investigational Site
Kavala, , Greece
Pfizer Investigational Site
Thessaloniki, , Greece
Pfizer Investigational Site
Thessaloniki, , Greece
Pfizer Investigational Site
Waterford, , Ireland
Pfizer Investigational Site
Arona, NO, , Italy
Pfizer Investigational Site
Bologna, , Italy
Pfizer Investigational Site
Cagliari, , Italy
Pfizer Investigational Site
Monza, MI, , Italy
Pfizer Investigational Site
Napoli, , Italy
Pfizer Investigational Site
Pisa, , Italy
Pfizer Investigational Site
Rieti, , Italy
Pfizer Investigational Site
Siena, , Italy
Pfizer Investigational Site
Bydgoszcz, , Poland
Pfizer Investigational Site
Szczecin, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Banská Bystrica, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Košice, , Slovakia
Pfizer Investigational Site
Prešov, , Slovakia
Pfizer Investigational Site
Prešov, , Slovakia
Pfizer Investigational Site
Ružomberok, , Slovakia
Pfizer Investigational Site
Trenčín, , Slovakia
Pfizer Investigational Site
Žilina, , Slovakia
Pfizer Investigational Site
Santiago de Compostela, A Coruña, Spain
Pfizer Investigational Site
Alcalá de Henares, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Pamplona, Navarre, Spain
Pfizer Investigational Site
Santa Cruz de Tenerife, Santa Cruz de Tenerife, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Valladolid, Valladolid, Spain
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Västerås, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5751019
Identifier Type: -
Identifier Source: org_study_id